



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/443930/2024

European Medicines Agency decision P/0354/2024

of 25 October 2024

on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMEA-001741-PIP01-14-M08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0354/2024

of 25 October 2024

on the acceptance of a modification of an agreed paediatric investigation plan for upadacitinib (Rinvoq), (EMA-001741-PIP01-14-M08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0288/2015 issued on 27 November 2015, the decision P/0363/2017 issued on 1 December 2017, the decision P/0322/2019 issued on 11 September 2019, the decision P/0347/2020 issued on 9 September 2020, the decision P/0167/2021 issued on 14 April 2021, the decision P/0510/2021 issued on 3 December 2021, the decision P/0237/2023 issued on 14 June 2023, and the decision P/0010/2024 issued on 31 January 2024,

Having regard to the application submitted by Abbvie Ltd on 31 May 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 September 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for upadacitinib (Rinvoq), age-appropriate oral solid dosage form, age-appropriate oral liquid dosage form, prolonged-release tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, SL6 4UB – Maidenhead, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/273617/2024
Amsterdam, 6 September 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001741-PIP01-14-M08

Scope of the application

Active substance(s):

Upadacitinib

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

Pharmaceutical form(s):

Age-appropriate oral solid dosage form

Age-appropriate oral liquid dosage form

Prolonged-release tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted to the European Medicines Agency on 31 May 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0288/2015 issued on 27 November 2015, the decision P/0363/2017 issued on 1 December 2017, the decision P/0322/2019 issued on 11 September 2019, the decision P/0347/2020 issued on 9 September 2020, the decision P/0167/2021 issued on 14 April 2021, the decision P/0510/2021 issued on



3 December 2021, the decision P/0237/2023 issued on 14 June 2023, and the decision P/0010/2024 issued on 31 January 2024.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 8 July 2024.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- age-appropriate oral solid dosage form, age-appropriate oral liquid dosage form, prolonged-release tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of juvenile idiopathic arthritis

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral solid dosage form

Age-appropriate oral liquid dosage form

Prolonged-release tablet

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of age-appropriate oral solid dosage form (dispersible tablet or multi-particulate granules) or age-appropriate oral liquid dosage form
Non-clinical studies	Study 2 Dose range-finding juvenile toxicity study

	Study 3 Definitive juvenile toxicity study to evaluate toxicity and impact of upadacitinib on neonatal/juvenile development
Clinical studies	Study 4 Open-label, multiple dose study to evaluate the pharmacokinetics, safety, and tolerability and to confirm the dosing regimen of upadacitinib in children with active polyarticular course juvenile idiopathic arthritis (JIA) Study 5 (study deleted during procedure EMEA-001741-PIP01-14-M05) Study 6 Randomised, open-label study to evaluate the safety, efficacy and pharmacokinetics (PK) of multiple-dose administration of upadacitinib with a tocilizumab reference arm in children with active systemic JIA
Extrapolation, modelling and simulation studies	Study 7 Population pharmacokinetic two compartment model that characterizes the pharmacokinetic parameters, the inter- and intra-subject variability, and relationship between pharmacokinetic parameters and the relevant covariates
Other studies	Not applicable
Other measures	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2028
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis and juvenile idiopathic arthritis)

Authorised indication(s):

- Rheumatoid arthritis
 - RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure
- Psoriatic arthritis
 - RINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure
- Ankylosing spondylitis
 - RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure
- Non-radiographic axial spondyloarthritis (nr-axSpA)
 - RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet

- Authorised route(s) of administration: Oral use
- Authorised via centralised procedure

2. Treatment of atopic dermatitis

Authorised indication(s):

- RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure

3. Treatment of ulcerative colitis

Authorised indication(s):

- RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure

4. Treatment of Crohn's Disease

Authorised indication(s):

- RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
 - Invented name(s): Rinvoq
 - Authorised pharmaceutical form(s): Prolonged-release tablet
 - Authorised route(s) of administration: Oral use
 - Authorised via centralised procedure